BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
Rhea-AI Summary
BioCardia (NASDAQ: BCDA) announced the election of Marvin Slosman to its Board of Directors, effective December 2, 2025, and the completion of Dr. Richard Krasno’s term on the same date. Slosman brings commercial and regulatory experience in interventional cardiology and medical devices, including executive roles at InspireMD, Johnson & Johnson, GE Healthcare, and Baxter.
Management highlighted Dr. Krasno’s contributions to clinical evidence for CardiAMP and the Morph DNA FDA approval, and thanked him for his service.
Positive
- Board addition: Marvin Slosman effective Dec 2, 2025
- Regulatory expertise: Slosman has regulatory and commercialization track record
- Regulatory milestone: Morph DNA received FDA approval (cited as completed)
Negative
- None.
News Market Reaction – BCDA
On the day this news was published, BCDA gained 3.65%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
BCDA was up 1.38% while several biotech peers like ADAP (-17.57%) and BCTX (-8.84%) traded lower, pointing to stock-specific dynamics rather than a sector-driven move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Board change | Positive | +3.6% | New director with cardiology and medtech experience joins, long-time member departs. |
| Dec 01 | Conference presentation | Positive | -4.1% | Company to present intramyocardial cell therapy data at heart failure congress. |
| Nov 24 | Leadership hire | Positive | +0.7% | Appointment of VP of Quality with >25 years regulatory and quality experience. |
| Nov 12 | Earnings and update | Positive | -3.1% | Q3 2025 results, $6M financing, trial progress, and regulatory plans disclosed. |
| Nov 10 | Clinical trial update | Positive | -0.8% | First patient enrolled at Henry Ford Health in Phase 3 CardiAMP HF II trial. |
Recent news (leadership, clinical, earnings, conferences) has led to relatively modest price moves, with a mix of small gains and declines rather than consistent direction.
Over the last month, BioCardia has reported leadership additions, clinical progress, and Q3 2025 results. Highlights included a $6.0M financing, ongoing Phase 3 CardiAMP HF II enrollment, and plans for a DeNovo 510(k) submission. Governance and quality leadership were strengthened with a new Vice President of Quality. The current board change continues this theme of organizational and strategic build-out following clinical and operational updates in November–December 2025.
Market Pulse Summary
This announcement centers on board refreshment, adding an experienced medtech executive while recognizing a long-serving director’s contributions. It follows recent leadership hires, clinical progress in the CardiAMP HF II Phase 3 trial, and Q3 2025 operational updates. Investors may focus on how governance and expertise support execution on trials, regulatory pathways, and commercialization plans, alongside monitoring future clinical data releases and financing developments.
Key Terms
fda approval regulatory
ischemic heart failure medical
acute myocardial infarction medical
pulmonary disease medical
AI-generated analysis. Not financial advice.
SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025.
“We are very pleased to welcome Mr. Slosman to our Board,” said Peter Altman, Chief Executive Officer of BioCardia. “With deep expertise in the interventional cardiology sector and a strong track record in advancing breakthrough technologies from concept to commercialization, Mr. Slosman brings an exceptional understanding of regulatory pathways, global market expansion, and clinical value creation. He will be a tremendous asset as we continue to scale our portfolio and deliver innovative solutions for patients and providers.”
Mr. Slosman currently serves as President, Chief Executive Officer, and Director of InspireMD, a NASDAQ listed medical device company focused on vascular and carotid-artery disease management solutions. In addition to experience as Chief Executive Officer, he has held positions as Chief Operating Officer, and senior commercial-leadership roles at major medical and healthcare companies, including Johnson & Johnson, GE Healthcare, and Baxter International Inc., helping drive commercialization and market development efforts. His background includes significant accomplishments in both public and private growth companies with expertise in regulatory pathways and approvals, strategic partnerships, product development, and operational and commercial growth in global medical technology markets.
CEO Altman also extended the Company’s gratitude to Dr. Richard Krasno for his years of service. “Dr. Krasno has been a dedicated and highly respected member of our Board,” said Mr. Altman. “During his tenure, he was instrumental in guiding the Company through key milestones, including clinical evidence development for the CardiAMP cell therapy for the treatment of ischemic heart failure, the Morph DNA product FDA approval, and expansion into new therapeutic areas of chronic myocardial ischemia acute myocardial infarction and pulmonary disease. We are deeply appreciative of his leadership and commitment to improving patient care.”
Dr. Krasno served on several Board committees, including the Audit Committee and the Compensation Committee, and contributed extensively to strengthening governance, and supporting long-term strategic planning for our development efforts.
The Board and executive leadership team welcome the expertise of Mr. Slosman and express sincere thanks to Dr. Krasno for his significant contributions to the Company’s mission of advancing therapies to treat cardiovascular disease.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: https://www.BioCardia.com.
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 26, 2025, under the caption titled “Risk Factors,” and in our subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact: Miranda Peto, Investor Relations Email: mpeto@BioCardia.com Phone: 650-226-0120 Investor Contact: David McClung, Chief Financial Officer Email: investors@BioCardia.com Phone: 650-226-0120
FAQ
When did BioCardia (BCDA) appoint Marvin Slosman to the board?
What experience does Marvin Slosman bring to BioCardia (BCDA)?
Why did Dr. Richard Krasno leave BioCardia's board (BCDA) and when?
What contributions did Dr. Richard Krasno make to BioCardia (BCDA)?
How might Marvin Slosman’s appointment affect BioCardia (BCDA) strategy?
